NKGen Biotech Announces Positive SNK01 Clinical Trial Results Presented at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

SANTA ANA, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- NKGen Biotech, a subsidiary of NKMax, harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies, today announced that data from a Phase 1/2a clinical trial, sponsored by NKMax, evaluating SNK01 (autologous natural...

Click to view original post